CJC-1295 (No DAC) / GHRP-6 Blend is a research peptide formulation combining two well-studied synthetic peptides frequently examined in growth hormone and endocrine signaling research: CJC-1295 without Drug Affinity Complex (No DAC) and Growth Hormone–Releasing Peptide-6 (GHRP-6). CJC-1295 (No DAC) is a modified growth hormone–releasing hormone (GHRH) analog, while GHRP-6 is a growth hormone secretagogue receptor (GHS-R) agonist originally developed as a hexapeptide. Together, this blend is formulated for laboratory research focused on growth hormone release dynamics, receptor signaling pathways, and metabolic regulation mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal approaches. In controlled research settings, CJC-1295 (No DAC) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a shorter duration of activity compared to DAC-bound variants. GHRP-6 has been widely researched for its role in ghrelin receptor activation and its effects on growth hormone secretion amplitude and frequency. The combination allows researchers to examine complementary mechanisms involved in pulsatile growth hormone signaling and coordinated pituitary response models.
Currently, the CJC-1295 (No DAC) / GHRP-6 Blend is being investigated for potential applications in metabolic research models, endocrine signaling analysis, recovery-related pathways, and age-associated hormone regulation studies. Additional research continues to explore its role in downstream anabolic signaling, appetite-related hormone interactions, and circadian growth hormone release patterns. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The CJC-1295 (No DAC), GHRP-6 Blend is designed for laboratory research exploring growth hormone signaling, endocrine pathway communication, and pulsatile hormone dynamics. By combining a growth hormone–releasing hormone analog with a growth hormone secretagogue, this blend allows researchers to examine how upstream hypothalamic signaling interacts with pituitary response mechanisms within controlled experimental models.
In research environments, peptide blends like this are frequently used to evaluate signaling interactions, pulse amplitude behavior, and downstream biomarker responses across defined sampling intervals. Because multi-variable peptide studies introduce additional experimental complexity, rigorous protocol design, endpoint clarity, and stable environmental controls are essential for maintaining data reliability and reproducibility.
CJC-1295 (No DAC), GHRP-6 Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | CJC-1295 (No DAC) + GHRP-6 |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
CJC-1295 without DAC is widely discussed in peptide research as a modified growth hormone–releasing hormone analog used to study pulsatile GH signaling patterns. Because this version lacks the Drug Affinity Complex (DAC) modification present in certain extended-duration variants, it is frequently used in experimental models where researchers want to evaluate shorter signaling windows and clearer pulse-response relationships.
GHRP-6 is a growth hormone secretagogue that has been studied in laboratory models involving ghrelin receptor pathways and endocrine signaling responses. In research settings, it may be used to evaluate pituitary response behavior, hormonal signaling cascades, and metabolic marker fluctuations associated with GH-axis activity.
When used together in a blended experimental design, these peptides allow researchers to examine how GHRH pathway stimulation and ghrelin receptor activation interact. Some studies explore whether dual-pathway signaling produces measurable differences in hormone pulse frequency, amplitude, or downstream metabolic signaling compared to single-variable models.
For researchers evaluating these pathways individually, additional product references are available for CJC-1295 (without DAC) and GHRP-6.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
One of the primary research applications of this blend is analyzing pulsatile growth hormone signaling patterns. Researchers may monitor time-dependent biomarker movement and endocrine responses to evaluate how combined pathway activation influences GH release behavior within controlled experimental systems.
Because both peptides interact with elements of the growth hormone axis, they are often used in endocrine research exploring pituitary responsiveness and hormone signaling pathways. Experimental models can track endocrine marker responses under standardized laboratory conditions.
Many laboratories run multi-arm experiments where blended peptide protocols are compared to single-peptide conditions. This structure helps researchers determine whether observed effects are additive, synergistic, or primarily attributable to one signaling pathway.
Growth hormone signaling research frequently overlaps with metabolic marker analysis in controlled experimental environments. Researchers may evaluate downstream variables including endocrine markers, metabolic indicators, and cellular signaling patterns that shift alongside GH-axis activity.
The CJC-1295 (No DAC), GHRP-6 Blend should be handled according to standard peptide laboratory protocols emphasizing sterile technique, contamination prevention, and proper storage practices. Accurate record keeping and environmental consistency help maintain reproducibility across experimental cohorts.
Protocol Design Considerations: Growth hormone signaling experiments are sensitive to circadian rhythm timing, baseline metabolic status, environmental stability, and stress variables. Standardized sampling windows and controlled research environments help improve data reliability.
Note: The information above is provided solely as a research reference summary. All experimental use must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis documenting identity and quality parameters. These analytical reports support research documentation, procurement verification, and reproducibility tracking across laboratory studies.
When sourcing peptides for endocrine signaling research, laboratories typically prioritize consistent product identity, traceable documentation, and reliable quality-control processes. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and structured procurement systems designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for complying with all applicable regulatory and institutional guidelines.
